MCID: MYL003
MIFTS: 48

Myeloid Sarcoma

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Myeloid Sarcoma

MalaCards integrated aliases for Myeloid Sarcoma:

Name: Myeloid Sarcoma 12 20 58 15 17 32
Granulocytic Sarcoma 12 20 58 17 70
Extramedullary Myeloid Tumor 12 20 58
Chloroma 12 20 58
Sarcoma, Granulocytic 73
Sarcoma Granulocytic 54
Sarcoma, Myeloid 44

Characteristics:

Orphanet epidemiological data:

58
myeloid sarcoma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8683
MeSH 44 D023981
NCIt 50 C35815
SNOMED-CT 67 188738007
ICD10 32 C92.3
MESH via Orphanet 45 D023981
ICD10 via Orphanet 33 C92.3
UMLS via Orphanet 71 C0152276
Orphanet 58 ORPHA86850
UMLS 70 C0152276

Summaries for Myeloid Sarcoma

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 86850 Definition Myeloid sarcoma is a rare solid tumor of the myelogenous cells occurring in an extramedullary site. Epidemiology The exact prevalence is unknown. Clinical description The clinical presentation depends on the site of involvement. Commonly involved sites of occurrence include the subperiosteal bone structures of the skull, paranasal sinuses, sternum, ribs, vertebrae, pelvis, as well as the lymph nodes and skin. Rare sites include the pancreas, heart, brain, mouth, breast, gastrointestinal and biliary tract, prostate, urinary bladder and gynecologic tract.

MalaCards based summary : Myeloid Sarcoma, also known as granulocytic sarcoma, is related to acute myeloblastic leukemia with maturation and childhood acute myeloid leukemia. An important gene associated with Myeloid Sarcoma is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and NF-kappaB Signaling. The drugs Mitoxantrone and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and pancreas, and related phenotypes are hematopoietic system and cellular

Wikipedia : 73 A myeloid sarcoma (chloroma, granulocytic sarcoma, extramedullary myeloid tumor), is a solid tumor... more...

Related Diseases for Myeloid Sarcoma

Diseases related to Myeloid Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 502)
# Related Disease Score Top Affiliating Genes
1 acute myeloblastic leukemia with maturation 30.9 NPM1 KIT FLT3
2 childhood acute myeloid leukemia 30.6 NPM1 KIT FLT3
3 acute myeloid leukemia with t(8;21)(q22;q22) translocation 30.4 KIT FLT3
4 myeloid leukemia 30.4 U2AF1 NPM1 MPO KMT2A KIT FLT3
5 monocytic leukemia 30.4 MPO KMT2A FLT3
6 leukemia 30.3 U2AF1 PAX5 NPM1 KMT2A KIT FLT3
7 anaplastic large cell lymphoma 30.3 PTPRC PAX5 NPM1
8 acute myeloblastic leukemia without maturation 30.3 NPM1 FLT3
9 small intestinal sarcoma 30.3 PTPRC KIT CD68
10 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.2 MPO KMT2A KIT FLT3 DNTT
11 thymoma 30.2 PTPRC KIT DNTT CD274
12 dendritic cell tumor 30.2 PTPRC MPO DNTT CD68
13 lymphoblastic lymphoma 30.2 PTPRC PAX5 MPO KMT2A DNTT
14 mediastinal malignant lymphoma 30.0 PAX5 CD79A
15 bladder sarcoma 30.0 KIT CD68 CD34
16 lymphoma, hodgkin, classic 30.0 PTPRC PAX5 IRF4 CD68
17 extracutaneous mastocytoma 30.0 U2AF1 KIT
18 hodgkin's lymphoma, nodular sclerosis 30.0 PAX5 CD79A
19 tonsillitis 29.9 MPO CD79A ANPEP
20 b-cell lymphoma 29.9 PTPRC PAX5 NPM1 IRF4 CD274
21 myeloproliferative neoplasm 29.9 U2AF1 MPO KMT2A KIT FLT3 CD274
22 rhabdomyosarcoma 29.9 PTPRC PAX5 NCAM1 KIT CD274
23 mast cell neoplasm 29.8 U2AF1 KIT FLT3
24 angiosarcoma 29.8 KIT CD68 CD34
25 cll/sll 29.8 SPN PAX5 CD79A
26 germinoma 29.7 U2AF1 PAX5 KIT
27 myelofibrosis 29.7 U2AF1 NPM1 MPO KIT FLT3 CD34
28 central nervous system leukemia 29.7 KMT2A CD34 CD33 ANPEP
29 lymphoma 29.7 PTPRC PAX5 NPM1 IRF4 DNTT CD274
30 ewing sarcoma 29.7 PTPRC NCAM1 KIT DNTT
31 testicular lymphoma 29.7 IRF4 CD79A CD274
32 chronic eosinophilic leukemia 29.6 U2AF1 KIT FLT3
33 langerhans cell histiocytosis 29.5 U2AF1 PTPRC CD68
34 aleukemic leukemia cutis 29.5 SPN NPM1 MPO CD33 ANPEP
35 reticulosarcoma 29.5 PTPRC PAX5 NPM1 CD68 ANPEP
36 peripheral t-cell lymphoma 29.4 PTPRC NCAM1 CD274
37 basal cell carcinoma 29.4 NCAM1 KIT CD68 CD34 CD274
38 chronic leukemia 29.3 U2AF1 KIT FLT3 CD34
39 plasmacytoma 29.3 PTPRC PAX5 NCAM1 IRF4 CD79A
40 lymphoma, mucosa-associated lymphoid type 29.3 SPN PTPRC PAX5 IRF4 CD79A
41 acute leukemia 29.2 PAX5 NPM1 NCAM1 MPO KMT2A KIT
42 chronic myelomonocytic leukemia 29.2 U2AF1 NPM1 MPO KMT2A KIT FLT3
43 leukemia, acute monocytic 29.1 U2AF1 MPO KMT2A FLT3 CD33
44 precursor t-cell acute lymphoblastic leukemia 29.1 MPO KMT2A FLT3 DNTT CD34 CD33
45 b-lymphoblastic leukemia/lymphoma 29.1 PTPRC PAX5 MPO KMT2A KIT FLT3
46 myelodysplastic syndrome 29.0 U2AF1 NPM1 MPO KMT2A KIT FLT3
47 leukemia, chronic myeloid 29.0 U2AF1 PTPRC MPO KMT2A KIT IRF4
48 gallbladder lymphoma 28.9 SPN PTPRC PAX5 IRF4 CD79A CD33
49 acute promyelocytic leukemia 28.8 PTPRC NPM1 NCAM1 MPO MIR181A1 KMT2A
50 mixed phenotype acute leukemia 28.7 U2AF1 MPO KMT2A FLT3 DNTT CD33

Graphical network of the top 20 diseases related to Myeloid Sarcoma:



Diseases related to Myeloid Sarcoma

Symptoms & Phenotypes for Myeloid Sarcoma

MGI Mouse Phenotypes related to Myeloid Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.16 ANPEP CD274 CD34 CD68 CD79A DNTT
2 cellular MP:0005384 10.06 CD274 CD34 CD79A FLT3 IRF4 KIT
3 immune system MP:0005387 10.06 ANPEP CD274 CD34 CD68 CD79A DNTT
4 neoplasm MP:0002006 9.65 CD34 CD79A FLT3 IRF4 KIT KMT2A
5 no phenotypic analysis MP:0003012 9.17 CD274 CD68 CD79A FLT3 KIT KMT2A

Drugs & Therapeutics for Myeloid Sarcoma

Drugs for Myeloid Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
2
Etoposide Approved Phase 3 33419-42-0 36462
3
Daunorubicin Approved Phase 3 20830-81-3 30323
4
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
5
Bortezomib Approved, Investigational Phase 3 179324-69-7 93860 387447
6
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
7
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
8 Analgesics Phase 3
9 Antimitotic Agents Phase 3
10 Tubulin Modulators Phase 3
11 Etoposide phosphate Phase 3
12 Keratolytic Agents Phase 3
13 Protein Kinase Inhibitors Phase 3
14
asparaginase Phase 3
15 Dermatologic Agents Phase 3
16 N-Methylaspartate Phase 3
17 Podophyllotoxin Phase 3 518-28-5
18
Mesna Approved, Investigational Phase 2 3375-50-6 598
19
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
20
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
21
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
22
Blinatumomab Approved, Investigational Phase 2 853426-35-4
23
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
24
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
25
Idarubicin Approved Phase 2 58957-92-9 42890
26
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
27
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
28
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
29
Melphalan Approved Phase 2 148-82-3 4053 460612
30
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
31
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
32
rituximab Approved Phase 2 174722-31-7 10201696
33
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
34
Lenograstim Approved, Investigational Phase 2 135968-09-1
35
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
36
Mycophenolic acid Approved Phase 2 24280-93-1 446541
37
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
38
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
39
Busulfan Approved, Investigational Phase 2 55-98-1 2478
40
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
41
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
42 Cordycepin Investigational Phase 2 73-03-0
43 Antifungal Agents Phase 2
44 razoxane Phase 2
45 Cardiotonic Agents Phase 2
46 2-chloro-3'-deoxyadenosine Phase 2
47 Gemtuzumab Phase 2
48 Immunoglobulins Phase 2
49 Antibodies, Monoclonal Phase 2
50 Antibodies Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD Active, not recruiting NCT01371981 Phase 3 Asparaginase;Bortezomib;Cytarabine;Daunorubicin Hydrochloride;Etoposide;Mitoxantrone Hydrochloride;Sorafenib Tosylate
2 Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting NCT02790515 Phase 2 Anti-thymocyte globulin (rabbit);Blinatumomab;Cyclophosphamide;Fludarabine;G-CSF;Melphalan;Mesna;Rituximab;Tacrolimus;Thiotepa;Sirolimus
3 Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms Recruiting NCT03589729 Phase 2 Cladribine;Cytarabine;Dexrazoxane Hydrochloride;Gemtuzumab Ozogamicin;Idarubicin
4 An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Active, not recruiting NCT02484391 Phase 2 6,8-Bis(benzylthio)octanoic Acid;Cytarabine;Mitoxantrone Hydrochloride
5 Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML Active, not recruiting NCT02658487 Phase 2 Cytarabine;Vosaroxin
6 CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Terminated NCT02259348 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Thiotepa;Rituximab
7 T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated NCT01621477 Phase 2 clofarabine;cytarabine;busulfan;Plerixafor;cyclophosphamide;antithymocyte globulin (rabbit);Tacrolimus;mycophenolate mofetil
8 A Pilot Study of Allogeneic Hematopoietic Cell Transplantation for Patients With High Grade Central Nervous System Malignancies Recruiting NCT04521946 Phase 1 Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus;Thiotepa
9 Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): an Observational Retrospective Multicentre Study on Patients Previously Registered in GIMEMA Clinical Trials Recruiting NCT03410407

Search NIH Clinical Center for Myeloid Sarcoma

Cochrane evidence based reviews: sarcoma, myeloid

Genetic Tests for Myeloid Sarcoma

Anatomical Context for Myeloid Sarcoma

MalaCards organs/tissues related to Myeloid Sarcoma:

40
Myeloid, Bone Marrow, Pancreas, Prostate, Cervix, Skin, Small Intestine

Publications for Myeloid Sarcoma

Articles related to Myeloid Sarcoma:

(show top 50) (show all 1780)
# Title Authors PMID Year
1
The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas. 61 54
18794057 2008
2
Preceding orbital granulocytic sarcoma in an adult patient with acute myelogenous leukemia with t(8;21): a case study and review of the literature. 54 61
18656695 2008
3
t(5;12)(q13;p13) in acute myeloid leukemia with preceding granulocytic sarcoma. 61 54
17854675 2007
4
Myeloid sarcoma presenting with acute renal failure and bilateral ureteral obstruction: a case report and review of the literature. 61 54
17700206 2007
5
Granulocytic sarcoma of breast: an aleukemic presentation. 61 54
17337816 2007
6
Myeloid sarcoma occurring concurrently with drug-induced gingival enlargement. 61 54
16579712 2006
7
Rearrangement of MLL in a patient with congenital acute monoblastic leukemia and granulocytic sarcoma associated with a t(1;11)(p36;q23) translocation. 54 61
15621793 2005
8
[A-leukemic caecal myeloid sarcoma: a difficult diagnosis]. 54 61
15738870 2004
9
FLT3 mutations in myeloid sarcoma. 61 54
15352981 2004
10
Extramedullary presentation of acute leukaemia: a case of myeloid/natural killer cell precursor leukaemia. 54 61
12959763 2003
11
Granulocytic sarcoma in MLL-positive infant acute myelogenous leukemia: fluorescence in situ hybridization study of childhood acute myelogenous leukemia for detecting MLL rearrangement. 54 61
11733351 2001
12
c-Kit (CD117) reactivity in extramedullary myeloid tumor/granulocytic sarcoma. 54 61
11698000 2001
13
The value of CD34, myeloperoxidase and chloroacetate esterase (Leder) stain in the diagnosis of granulocytic sarcoma. 54 61
17261930 2001
14
[Granulocytic sarcoma presenting as an epidural mass with spinal cord compression]. 61 54
11020993 2000
15
CD30+ anaplastic large-cell lymphoma with aberrant expression of CD13: case report and review of the literature. 54 61
11138613 2000
16
Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. 61 54
8902835 1996
17
Granulocytic sarcoma with expression of CD30. 61 54
9038763 1996
18
Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia. 54 61
8907283 1996
19
Extramedullary tumors of lymphoid or myeloid blasts. The role of immunohistology in diagnosis and classification. 61 54
7572794 1995
20
Immunohistochemical differential diagnosis of granulocytic sarcomas and malignant lymphomas on formalin-fixed material. 61 54
2106752 1990
21
Myelodysplastic syndrome presenting with generalized cutaneous granulocytic sarcomas. 54 61
2154905 1990
22
Rare presentation of isolated bilateral testicular myeloid sarcoma: A case report. 61
33552919 2021
23
Myeloid sarcoma of the pancreas: A case report and literature review. 61
33787578 2021
24
A clinical report of intracranial granulocytic sarcoma and a literature review. 61
33272089 2021
25
Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study. 61
33692532 2021
26
Myeloid sarcoma diagnosed on pleural effusion cytology: A case report and literature review. 61
33751858 2021
27
Unexplained ascites caused by myeloid sarcoma with omentum involvement. 61
33733805 2021
28
Granulocytic sarcoma: Study of two cases by high throughput sequencing. 61
32199632 2021
29
The utility of fine needle aspiration cytology in orbital haematolymphoid neoplasms. 61
33125778 2021
30
Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. 61
33416901 2021
31
Cardiac Myeloid Sarcoma: Multimodal Imaging and Histopathologic Findings. 61
33778664 2021
32
Diagnosis and surgical treatment of primary isolated aggressive lumbar myeloid sarcoma: a rare case report and review of the literatures. 61
33627110 2021
33
Leonine facies as the initial manifestation of CD56+ myeloid sarcoma. 61
33586657 2021
34
Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow. 61
33108522 2021
35
Characteristics and prognosis of pediatric myeloid sarcoma in the cytogenetic context of t(8;21). 61
32803999 2021
36
How I diagnose and treat NPM1-mutated AML. 61
33171486 2021
37
[The Impact of Induction Treatment Response on the Prognosis of Pediatric Core Binding Factor-Acute Myeloid Leukemia Patients]. 61
33554797 2021
38
Genomic analysis in myeloid sarcoma and comparison with paired acute myeloid leukemia. 61
33232718 2021
39
Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. 61
32606455 2021
40
Primary Myeloid Sarcoma of Ovary: A Case Report and Review of the Literature. 61
33432557 2021
41
18F-FDG PET/CT Imaging of Testicular Myeloid Sarcoma in a Pediatric Patient. 61
33181756 2021
42
[Myeloid sarcoma]. 61
32353885 2021
43
Characteristics and transplant outcome of myeloid sarcoma: a single-institute study. 61
33511548 2021
44
Case Report: Myeloid Sarcoma Development During Treatment for B Cell Lymphoblastic Lymphoma in a Boy with KRAS/NRAS Gene Mutations. 61
33469311 2021
45
Extramedullary Blast Crisis of Chronic Myelogenous Leukemia With a Skin Lesion: A Case Report and Literature Review. 61
33481378 2021
46
Mass-forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia. 61
33314782 2020
47
Hematolymphoid Neoplasms Rarely Mimic Undifferentiated Pleomorphic Sarcoma of Soft Tissue. 61
32167380 2020
48
A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma presenting with extensive skin involvements and the results of genetic study. 61
33327223 2020
49
MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma. 61
33405278 2020
50
Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. 61
33166908 2020

Variations for Myeloid Sarcoma

Expression for Myeloid Sarcoma

Search GEO for disease gene expression data for Myeloid Sarcoma.

Pathways for Myeloid Sarcoma

GO Terms for Myeloid Sarcoma

Cellular components related to Myeloid Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.5 SPN PTPRC NCAM1 KIT CD34 CD33
2 external side of plasma membrane GO:0009897 9.28 SPN PTPRC NCAM1 KIT CD79A CD34

Biological processes related to Myeloid Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.85 PTPRC NPM1 NCAM1 FLT3 ANPEP
2 neutrophil degranulation GO:0043312 9.77 PTPRC MPO CD68 CD33 ANPEP
3 MAPK cascade GO:0000165 9.73 PEBP1 NCAM1 KIT FLT3
4 negative regulation of tumor necrosis factor production GO:0032720 9.58 MIR181A1 CD34 CD33
5 hemopoiesis GO:0030097 9.5 KIT FLT3 CD34
6 positive regulation of interleukin-10 production GO:0032733 9.33 IRF4 CD34 CD274
7 myeloid progenitor cell differentiation GO:0002318 9.26 KIT FLT3
8 positive regulation of protein tyrosine phosphatase activity GO:1903615 8.96 PTPRC CD33
9 B cell differentiation GO:0030183 8.92 PTPRC KIT FLT3 CD79A

Sources for Myeloid Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....